Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · IEX Real-Time Price · USD
1.430
+0.080 (5.93%)
Apr 23, 2024, 3:09 PM EDT - Market open
CNTB Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CNTB stock have an average target of 6.50, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 354.55% from the current stock price of 1.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CNTB stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +459.44% | Apr 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +389.51% | Mar 4, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $5 | Buy | Reiterates | $5 | +249.65% | Sep 13, 2023 |
| SVB Leerink | SVB Leerink | Buy Maintains $9 → $7 | Buy | Maintains | $9 → $7 | +389.51% | Feb 8, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $5 | Buy | Initiates | $5 | +249.65% | Jun 2, 2022 |
Financial Forecast
Revenue This Year
621.70M
Revenue Next Year
259.89M
from 621.70M
Decreased by -58.20%
EPS This Year
-3.98
from -1.08
EPS Next Year
-5.59
from -3.98
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 906.7M | 377.0M | 40.4M | 76.1M | 299.1M |
| Avg | 621.7M | 259.9M | 39.2M | 73.9M | 290.5M |
| Low | 348.4M | 147.5M | 37.7M | 71.0M | 279.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | -39.4% | -84.5% | 94.1% | 304.7% |
| Avg | - | -58.2% | -84.9% | 88.5% | 293.1% |
| Low | - | -76.3% | -85.5% | 81.2% | 277.7% |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | -4.10 | -5.75 |
| Avg | -3.98 | -5.59 |
| Low | -3.82 | -5.37 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.